EC Number   |
Title |
Organism |
|---|
    3.1.4.17 | Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors |
Homo sapiens |
| 3.1.4.17 | Discovery of a novel series of pyrazolo[1,5-a]pyrimidine-based phosphodiesterase 2A inhibitors structurally different from N-((1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the treatment of cognitive disorders |
Homo sapiens |
| 3.1.4.17 | Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span |
Homo sapiens |
| 3.1.4.17 | Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span |
Mus musculus |
| 3.1.4.17 | Identification of the cAMP phosphodiesterase CpdA as novel key player in cAMP-dependent regulation in Corynebacterium glutamicum |
Corynebacterium glutamicum |
| 3.1.4.17 | Identification of the cAMP phosphodiesterase CpdA as novel key player in cAMP-dependent regulation in Corynebacterium glutamicum |
Corynebacterium glutamicum ATCC 13032 |
| 3.1.4.17 | Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure |
Mus musculus |
| 3.1.4.17 | Revisiting bacterial cyclic nucleotide phosphodiesterases cyclic AMP hydrolysis and beyond |
Anabaena sp. |
| 3.1.4.17 | Revisiting bacterial cyclic nucleotide phosphodiesterases cyclic AMP hydrolysis and beyond |
Myxococcus xanthus |
| 3.1.4.17 | Revisiting bacterial cyclic nucleotide phosphodiesterases cyclic AMP hydrolysis and beyond |
Pseudomonas aeruginosa |
